Association Between Glycemic Control and Hematological Indices in Type 2 Diabetes Mellitus: A Cross-sectional Study
Keywords:
Type 2 Diabetes Mellitus, Glycemic Control, Hematological Parameters, HbA1c, Inflammation, Platelet Indices, Neutrophil-to-Lymphocyte Ratio, Anemia, Chronic Inflammation, Diabetes ComplicationsAbstract
Background: Type 2 diabetes mellitus (T2DM) is a major preventable cause of morbidity due to its chronic complications. Emerging evidence suggests that hyperglycemia affects hematological parameters, which may serve as accessible indicators of disease severity and associated risks.
Objective: This study aimed to evaluate the impact of glycemic control on hematological indices among patients with T2DM.
Materials and Methods: A cross-sectional study was conducted involving 300 patients with T2DM. Participants were categorized into two groups based on glycemic control: Group A with controlled diabetes (HbA1c <7%) and Group B with uncontrolled diabetes (HbA1c >7%). Data on clinical history, laboratory findings, and hematological parameters were collected and analyzed.
Results: Of the 300 patients, 115 (38.3%) had controlled diabetes and 185 (61.7%) had uncontrolled diabetes. Patients with poor glycemic control showed significantly higher levels of total leukocyte count (TLC), monocytes, basophils, red cell distribution width (RDW-CV), platelet distribution width (PDW), mean platelet volume (MPV), platelet large cell ratio (P-LCR), plateletcrit (PCT), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) (p < 0.05). Conversely, red blood cell (RBC) count, hemoglobin, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were significantly lower in this group (p < 0.05). HbA1c levels showed positive correlations with TLC, neutrophils, basophils, PDW, MPV, PCT, NLR, and PLR, and negative correlations with RBC count, hemoglobin, hematocrit (HCT), and MCV.
Conclusion: Poor glycemic control in T2DM is associated with increased inflammatory and prothrombotic markers. Routine hematological indices, being cost-effective and readily available, can serve as useful indicators to assess the severity and complications of diabetes..
Downloads
Metrics
References
Global Burden of Diabetes. International DiabetesFederation. IDF Diabetes Atlas, 10th ed. Brussels,Belgium. 2021. Avai lable at: ht tps: //www.diabetesatlas.org
.Zimmet P, Alberti KG, Shaw J. Global and societalimplications of the diabetes epidemic. Nature2001;414(6865):782–787.
. Kopelman PG. Obesity as a medical problem. Nature2000;404(6778):635–643.
. Fox CS, Coady S, Sorlie PD, et al. Increasingcardiovascular disease burden due to diabetesmellitus: the Framingham Heart Study. Circulation2007;115(12):1544–1550.
Preis SR, Pencina MJ, Hwang SJ, et al. Trends incardiovascular disease risk factors in individuals withand without diabetes mellitus in the FraminghamHeart Study. Circulation 2009;120(3):212–220.
Agrawal NK, Kant S. Targeting inflammation indiabetes: newer therapeutic options. World J Diabetes2014;5:697–710.
. Horne BD, Anderson JL, John JM, et al. Which whiteblood cell subtypes predict increased cardiovascularrisk? J Am Coll Cardiol 2005;45:1638–1643.
Beckman JA, Creager MA, Libby P. Diabetes andatherosclerosis: epidemiology, pathophysiology, andmanagement. JAMA 2002;287:2570–2581.
. Gasparyan AY, Ayvazyan L, Mikhailidis DP, et al. Meanplatelet volume: a link between thrombosis andinflammation? Curr Pharm Des 2011;17:47–58.
. Zaccardi F, Rocca B, Pitocco D, et al. Platelet meanvolume, distribution width, and count in type 2diabetes, impaired fasting glucose, and metabolicsyndrome: a meta-analysis. Diabetes Metab Res Rev2015;31:402–410.
. Ergelen M, Uyarel H, Altay S, et al. Predictive value ofelevated neutrophil to lymphocyte ratio in patientsundergoing primary angioplasty for ST-segmentelevation myocardial infarction. Clin Appl ThrombHemost 2014;20:427–432.
O’Malley T, Langhorne P, Elton RA, et al. Platelet sizein stroke patients. Stroke 1995;26:995–999.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
